While noncanonic xanthine nucleotides XMP/dXMP play an important role in balancing and maintaining intracellular purine nucleotide pool as well as in potential mutagenesis, surprisingly, acyclic nucleoside phosphonates bearing a xanthine nucleobase have not been studied so far for their antiviral properties. Herein, we report the synthesis of a series of xanthine-based acyclic nucleoside phosphonates and evaluation of their activity against a wide range of DNA and RNA viruses. Two acyclic nucleoside phosphonates within the series, namely 9-[2-(phosphonomethoxy)ethyl]xanthine (PMEX) and 9-[3-hydroxy-2-(phosphonomethoxy)propyl]xanthine (HPMPX), were shown to possess activity against several human herpesviruses. The most potent compound was PMEX, a xanthine analogue of adefovir (PMEA). PMEX exhibited a single digit mM activity against VZV (EC 50 ¼ 2.6 mM, TK þ Oka strain) and HCMV (EC 50 ¼ 8.5 mM, Davis strain), while its hexadecyloxypropyl monoester derivative was active against HSV-1 and HSV-2 (EC 50 values between 1.8 and 4.0 mM). In contrast to acyclovir, PMEX remained active against the TK -VZV 07-1 strain with EC 50 ¼ 4.58 mM. PMEX was suggested to act as an inhibitor of viral DNA polymerase and represents the first reported xanthine-based acyclic nucleoside phosphonate with potent antiviral properties.
Introduction
The concentration and ratio of purine nucleotides and deoxynucleotides in the nucleotide pool is highly regulated in order to maintain the proper function and genetic stability of mammalian cells. 1 Imbalances in (deoxy)nucleotide pool may have mutagenic consequences 2 and may lead to various diseases, such as combined immunodeficiency (loss of purine nucleoside phosphorylase (PNP) function), 3 hyperuricemia (loss of hypoxanthine-guanine phosphoribosyltransferase (HGPRT) function) 4 or cancer (uncontrollable activity of inosine-5 0 -monophosphate dehydrogenase, IMPDH). 5 Xanthosine monophosphate (XMP, 1, Figure 1 ) is an important intermediate in the de novo synthesis of guanine nucleotides and its concentration is essential for the maintenance of guanine nucleotide pool, where XMP serves as a substrate for guanosine monophosphate synthase, 7 that produces guanosine monophosphate (GMP). XMP is formed either from inosine monophosphate (IMP) by IMPDH or via salvage pathway using hypoxanthine or xanthine phosphoribosyltransferase. The XMP level is regulated by 5 0 -nucleotidase that hydrolyzes XMP to xanthosine. In contrast, the corresponding deoxyribonucleotide analogues, dXMP (2, Figure 1 ) and dXTP, are catabolic products of dGMP and dGTP enzymatic hydrolysis, or can be formed by defective purine nucleotide metabolism (involving deaminase enzymes), 8 or by chemical hydrolysis 9 of dGMP/dGTP via NO x -mediated nitrosative stress. 10 These processes can lead to a substantial incorporation of xanthine nucleotides into DNA and/ or RNA, 8 and subsequently to RNA miscoding and mutagenesis. 11 Moreover, deaminated nucleotides can interfere with RNA editing 12 and with functions of noncoding RNAs. 13 Under cell physiological homeostasis, the concentration and ratio of potentially mutagenic nucleotide intermediates, such as (d)IDP/(d)ITP/(d)XTP, is maintained by housekeeping enzymes, 14 especially those from nudix family such as ITPases/XTPpases, 15, 16 NUDT 16 or ITPA, 17 that can hydrolyze corresponding nucleoside di-or triphosphates. The main function of housekeeping enzymes is to prevent or minimize the incorporation of noncanonical nucleotides into DNA/ RNA. Unfortunately, the literature on housekeeping enzymes hydrolyzing dXDP/dXTP has been quite rare up to date.
Herpesviruses
18 are DNA-containing enveloped viruses from large Herpesviridae family and include herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV), and Epstein-Barr virus (EBV). Although current anti-herpetic therapy uses powerful antivirotics such as nucleoside analogues (acyclovir (ACV), penciclovir, vidarabine, and ganciclovir (GCV)), acyclic nucleoside phosphonate (ANP) cidofovir (CDV) (3, Figure 1 ), 19 or diphosphate mimic foscarnet, 20 many drug insensitive viruses have been identified in the clinics. The origin of virus resistance for HSV, VZV or CMV comes mostly from treatment using DNA polymerase inhibitors, such as ACV and GCV, where various alterations in the viral thymidine kinase gene [UL23 (HSV) and ORF36 (VZV)], protein kinase [UL97 (CMV)] and/or viral DNA polymerase gene [UL30 (HSV), ORF28 (VZV) and UL54 (CMV)] may occur. [21] [22] [23] As recent literature has shown, 24 the presence of resistant herpesviruses should be considered seriously not only in the case of immunocompromised individuals. Evidently, there is an urgent need for novel potent anti-herpetic agents with high barrier of resistance development.
ANPs, 25 mimics of natural nucleotides (avoiding the first phosphorylation step), represent a potent group of antiviral agents. ANPs are converted inside the cells to their diphosphates (ANPpp) that target DNA polymerase -viral and/or cellular. 19 These nucleoside triphosphate analogues act as competitive inhibitors and/or alternative substrates of the respective enzymes, in the later case leading to termination of DNA chain elongation. 19 Although some ANPs derived from xanthine were studied before as potential antiviral agents (namely the 9-[3-fluoro-2-(phosphonomethoxy)propyl] derivative, FPMPX), 26 the general lack of interest in such compounds was probably caused by their relatively complicated synthesis, since simple alkylation of xanthine base was expected to give a mixture of several regioisomers as well as polyalkylated products. Recently, we have reported 27 a simple and highyielding synthesis of xanthine ANPs exploiting the MW-assisted hydrolysis of the corresponding 2,6-dichloropurine derivatives. Here, we report the synthesis and antiviral evaluation of a series of xanthinebased ANPs (compounds 4-9, Figure 1 ), designed as non-hydrolyzable analogues of dXMP/XMP.
Chemistry
The synthesis of 9-[2-(phosphonomethoxy)ethyl]xanthine (PMEX, 4, Scheme 1), a xanthine analogue of the well-known antiviral agent adefovir (PMEA), 28 has been reported by our group earlier. 27 The microwave-assisted hydrolysis of 2,6-dichloropurine derivative 10 29 in aqueous HCl afforded the desired xanthine compound 4 in a 85% yield.
For the synthesis of other target ANPs, compounds 5-9 (Scheme 2), previously reported 26,30-34 guanine containing ANPs 11-15, have been exploited as a starting material. Standard diazotization of compounds 11-15 followed by 2-hydroxy-dediazoniation afforded the desired xanthine-based ANPs 5-9 in moderate to good yields (36-82%).
Since PMEX (4) exhibited promising antiviral properties, we decided to prepare several PMEX prodrugs in order to improve the compound permeability which might be limited for this negatively charged compound. At first, N 6 -cyclopropylaminopurine derivative 17 (Scheme 3) was prepared in a 75% yield from the corresponding N
6
-cyclopropyl-2,6-diaminopurine derivative 16, 35 using the above mentioned diazotization/2-hydroxy-dediazoniation procedure. Compound 17 was expected to be enzymatically converted (deaminated) to PMEX in an analogy to com- pound GS-9219 (an acyclic nucleotide analogue with potent antineoplastic activity), 36 and abacavir (a carbocyclic nucleoside used for the treatment of HIV infection). 37 Next, PMEX hexadecyloxypropyl (HDP) monoester 18 (Scheme 4), a prodrug approach developed by Hostetler et al. as a mimic of natural lipids, 38 was prepared from PMEX (4) and hexadecyloxypropyl alcohol via DCC-mediated coupling in a 23% yield. Similarly, phosphonate ester 19 (Scheme 4) bearing a perfluorinated-C12 chain was prepared by the same procedure in a 30% yield. Finally, the bisamidate prodrug 20 (Scheme 4) was obtained in a 13% yield starting from PMEX (4) and isopropyl ester of L-phenylalanine using the previously described procedure developed in our lab. 39 In order to confirm the expected mode of action of PMEX (4), i.e. viral DNA polymerase inhibition, the corresponding phosphonodiphosphate 21 (Scheme 5), as an analogue of natural nucleoside triphosphate, was also prepared. The two-step synthesis via a morpholidate intermediate 40 afforded, after the HPLC purification, the desired triphosphate mimic 21 in a low (3%) yield.
Biology
The synthesized xanthine-based ANPs (compounds 4-9) were evaluated for inhibitory activity against a wide range of DNA and RNA viruses: in human embryonic lung (HEL) cells (herpes simplex virus-1 (KOS strain), herpes simplex virus-2 (G strain), thymidine kinase deficient (ACV resistant) herpes simplex virus-1 (TK -KOS ACV r ), vaccinia virus, vesicular stomatitis virus, human cytomegalovirus (HCMV) (AD-169 strain and Davis strains), VZV (TK þ VZV strain and TK -VZV strains)), in HeLa cell cultures (vesicular stomatitis virus, Coxsackie virus B4 and respiratory syncytial virus (RSV)), in Vero cell cultures (para-influenza-3 virus, reovirus-1, Sindbis virus, Coxsackie virus B4, Punta Toro virus, yellow fever virus), in CrFK cell cultures (feline corona virus (FIPV)), and in MDCK cell cultures (influenza A virus (H1N1 and H3N2 subtypes) and influenza B virus). GCV, CDV, ACV, brivudin (BVDU), zalcitabine, zanamivir, alovudine, amantadine, rimantadine, ribavirin, dextran sulfate (molecular weight 10000, DS-10000), mycophenolic acid, Hippeastrum hybrid agglutinin (HHA), and Urtica dioica agglutinin (UDA) were used as the reference compounds. The antiviral activity was expressed as the EC 50 , i.e. compound concentration required to decrease virus plaque formation (VZV) or virusinduced cytopathogenicity (other viruses) by 50%. While none of the compounds showed any activity against RNA viruses, compounds 4, 5 and 6 were able to inhibit the replication of herpesviruses (Tables 1 and 2 ). PMEX (4) emerged as the most active compound against VZV and HCMV, being as active as the reference drug ACV against the TK replication of HCMV with EC 50 values of the same order of magnitude as the reference anti-HCMV drug GCV, while PMEX had a 50% cytostatic concentration of 111 mM for HEL cells. Thus, compound 4 was not only potent but also selective as the calculated selectivity indices (ratio CC 50 /EC 50 ) were of 24 and 42 (VZV 07-1 and Oka strains, respectively) and of 11 and 13 (HCMV AD-169 and Davis strains, respectively). Compounds 5 and 6 were, respectively, 6 to 12 folds and 3 to 8 folds less active than PMEX against VZV and HCMV. However, compounds 4, 5 and 6 inhibited the replication of HSV-1, HSV-2 and TK-HSV-1 at equivalent EC 50 values in the range of 16 to 39 mM. PMEX (4) lacked activity against vaccinia virus, while HPMPX compounds (both S-isomer 6 and racemic mixture 5) were weak inhibitors of this poxvirus (EC 50 ¼ 39 mM, Table 2 ). ANPs, including PMEX, are polar compounds, showing severely limited bioavailability. To increase the likelihood of good cell wall permeability, several different prodrug approaches were tested for PMEX (Tables 3 and 4 ). Compound 17 was completely inactive in all assays. Phosphonate ester 19 and biamidate prodrug 20 did not display any potent antiherpesvirus activity which might be explained by insufficient prodrug activation in these cells. The HDP-PMEX prodrug 18 proved to be 7 to 26 folds (VZV), 52 to 170 folds (HCMV) and 6 to 12 folds (HSV) more active compound than the parent compound 4, although a concomitant increase in its cytostatic activity of 11-fold was also observed indicating successful increase in the cell uptake. In order to determine whether the DNA polymerase was the actual target of action of PMEX (4), the compound was evaluated against well-characterized HSV-1 mutant viruses. Alike all ANPs, PMEX remained active against viruses bearing mutations in the viral TK (Figure 2) . Importantly, an increase in the EC 50 of PMEX of the same magnitude as that measured for the ANP adefovir 28 was found for DNA polymerase mutant viruses indicating that the target of action of the active form of compound 4 (i.e. PMEXpp) is the herpesvirus DNA polymerase.
The inhibitory activity of the diphosphate form of PMEX (PMEXpp, 21) was evaluated in an enzymatic assay against herpes (VZV and HCMV) DNA polymerases compared to cellular (a and b) DNA polymerases (Table 5 ). The inhibition of ACV triphosphate and the pyrophosphate analogue of foscarnet (PFA) were determined in this study for comparison. Compound 21 was not inhibitory towards cellular DNA polymerases, while it inhibited VZV DNA polymerase when dGTP was used as the competitive radiolabeled substrate (IC 50 ¼ 7.4 mM). However, no activity at the highest concentration of 21 (100 mM) could be detected against HCMV DNA polymerase when either dGTP or dTTP were used as the competitive radiolabeled substrates. These data suggest that compound 21 is a poor inhibitor of HCMV DNA polymerase or that the compound 13 C NMR) as internal standard or referenced to the residual solvent signal. HR MS spectra were taken on a LTQ Orbitrap XL spectrometer. The purity of the tested compounds was determined by HPLC (H 2 O-CH 3 CN, linear gradient) and was higher than 95%.
Method A. General procedure for diazotization/ 2-hydroxy-dediazoniation of guanine-based starting compounds
Guanine-based phosphonate (0.5 mmol) was dissolved in 80% AcOH (20 mL) and excess of isoamylnitrite (2.0 mL) was added. The reaction mixture was stirred at 20 C for 16 h. Volatiles were evaporated, and the residue was co-evaporated with water (3 Â 10 mL) and evaporated to dryness. The crude product was dissolved in a small amount of water and purified by preparative HPLC in 0.1 M TEAB buffer using gradient water/methanol (from 98/2 to 20/80).
((2-(2,6-Dioxo-1,2,3,6-tetrahydro-9H-purin-9-yl)ethoxy) methyl)phosphonic acid (4), PMEX. Synthesis of compound 4 was performed from compound 10 (2.0 g, 4.86 mmol), using previously described procedure. 27 Microwave-assisted heating (130 C, 20 min) of compound 10 in aqueous HCl (1.0 M), followed by solvent removal and precipitation form a water/methanol mixture gave 4 (1.2 g, 85%) as a white solid. The analytical data are in an agreement with the published data. 27 (RS)-(( (1-(2,6-Dioxo-1,2,3,6 -tetrahydro-9H-purin-9-yl)-3-hydroxypropan-2-yl)oxy)methyl)phosphonic acid (5) (R)-(( (1-(2,6-Dioxo-1,2,3,6 -tetrahydro-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphonic acid (9), (R)-PMPX. Treatment of 15 (250 mg, 0.82 mmol) by Method A gave 9 (129 mg, 51%) as a white solid. 3-(Hexadecyloxy)propyl hydrogen ((2-(2,6-dioxo-1,2,3,6-tetrahydro-9H-purin-9-yl)ethoxy)methyl)phosphonate (18) . A suspension of 4 (100 mg, 0.31 mmol) and 3-(hexadecyloxy)propan-1-ol (124 mg, 0.41 mmol) in anhydrous pyridine (10 mL) was preheated to 100 C. Dicyclohexylcarbodiimide (142 mg, 0.69 mmol) in anhydrous pyridine (3 ml) was added and the reaction mixture was stirred at 100 C for 16 h. Solvent was evaporated and the crude product was purified using silica gel chromatography (CHCl 3 /MeOH, 0-50%) to give 18 (46 mg, 23%) as a white amorphous solid. 4, 4, 5, 5, 6, 6, 7, 7, 8, 8, 9, 9, 10, 10, 11, 11, ((2-(2,6-dioxo-1,2,3,6-tetrahydro-9H-purin-9-yl) ethoxy)methyl)phosphonate (19) . A suspension of 4 (100 mg, 0.31 mmol) and 4,4,5,5,6,6,7,7,8,8,9,9,10, 10,11,11,11-heptadecafluoroundecan-1-ol (198 mg, 0.41 mmol) in anhydrous pyridine (10 mL) was preheated to 100 C. Dicyclohexylcarbodiimide (142 mg, 0.69 mmol) in anhydrous pyridine (3 ml) was added and the reaction mixture was stirred at 100 C for 16 h. Solvent was evaporated and the crude product was purified using silica gel chromatography (CHCl 3 / MeOH, 0-50%) to give 19 (78 mg, 30%) as a white amorphous solid. Bis(L-phenylalanine isopropyl ester) ((2-(2,6-dioxo-1,2,3,6-tetrahydro-9H-purin-9-yl)ethoxy)methyl)phosphonate (20) . TMSBr (330 mL) was added to the mixture of 4 (117 mg, 0.33 mmol) in dry pyridine (4 ml) and DMF (1 ml). The reaction mixture was stirred at 25 C for 16 h. Volatiles were removed and the moisture-sensitive product was permanently kept under argon. Solid isopropyl ester L-phenylalanine hydrochloride (330 mg, 1.4 mmol) was added to the silylated intermediate under argon, followed by dry pyridine (5 ml) and dry Et 3 N (660 ml, 4.7 mmol). The mixture was preheated to 70 C and freshly prepared solution of aldrithiol-2 (0.45 g, 2.0 mmol) and triphenylphosphine (0.54 g, 2.0 mmol) in pyridine (4 ml) was added. The resulting mixture was stirred at 70 C for 72 h. Reaction mixture was evaporated in vacuo and the residue was purified by column chromatography (0-100% MeOH in a mixture of Hexane:EtOAc, 6:4) followed by C18 reversed phase column chromatography (0-100% MeOH in water) to give 20 (30 mg, 13%) as an amorphous white solid. C overnight. After cooling down, solids were filtered off, and the mixture was concentrated up to half of the volume, and diluted with water (200 ml). The aqueous solution was extracted with diethyl ether (3 Â 10 mL) and the organic layer was dried (Na 2 SO 4 ) and evaporated to dryness. Crude morpholidate was used directly for the pyrophosphate coupling.
Pyrophosphate coupling: Prepared morpholidate (0.2 mmol) was carefully dried over P 2 O 5 and treated with (NHBu 3 ) 2 H 2 P 2 O 7 (0.5 M solution in DMF, 3 ml) at room temperature for 48 h. The product was precipitated with diethyl ether (10 ml) and the solid was washed with diethyl ether (10 ml). The precipitated product was dissolved in 0.05 M TEAB (4 ml) and purified on a column packed with POROS V R 50 HQ (50 ml) with use of a gradient of TEAB in water (0.05-0.5 M). The product was co-evaporated several times with water and converted into a sodium salt form (Dowex 50 in Na þ cycle). Lyophylisation afforded 21 (5 mg, 3%) as a white amorphous solid. Compound 4 was evaluated against several TK and DNA polymerase mutants derived from the reference Kos strain by CPE reduction assay using as reference drugs ACV, GCV, BVDU, foscavir, CDV and adefovir (ADV).
Cytotoxicity of the tested compounds was expressed as the minimum cytotoxic concentration or the compound concentration that caused a microscopically detectable alteration of cell morphology. Alternatively, the cytostatic activity of the test compounds was measured based on the inhibition of cell growth. HEL cells were seeded at a rate of 5 Â 10 3 cells/ well into 96-well microtiter plates and allowed to proliferate for 24 h. Then, medium containing different concentrations of the test compounds was added. After three days of incubation at 37 C, the cell number was determined with a Coulter counter. The cytostatic concentration was calculated as the CC 50 , or the compound concentration required reducing cell proliferation by 50% relative to the number of cells in the untreated controls.
The inhibitory effects of PMEXpp on human (a and b) and viral (VZV and HCMV) DNA polymerases were determined as previously described using activated calf thymus DNA, 100 mM of each of the three unlabeled dNTPs, and 0.5 mM of the rate limiting tritiumlabeled dNTP, and serial dilutions of PMEXpp (21) . Foscarnet pyrophosphate and acyclovir triphosphate (ACV-TP) were included as the reference compound. The 50% inhibitory concentration or compound concentration required to inhibit the polymerase-catalyzed DNA synthesis by 50% was then determined.
